kappa-Opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine

被引:0
|
作者
Shippenberg, TS
LeFevour, A
Heidbreder, C
机构
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A place preference conditioning procedure was used to examine the influence of kappa-opioid receptor ligands upon the development of sensitization to the conditioned rewarding effects of cocaine. Previous exposure to cocaine (10-20 mg/kg; i.p.; days 1-5) resulted in an enhancement of the conditioned rewarding effects of this agent, e.g., sensitization, Thus, doses of cocaine (5.0-10.0 mg/kg; i.p.) that failed to produce place preferences in control rats produced significant place preferences in cocaine-experienced animals. In animals that had received the kappa-agonist U50,488H (5.0 mg/kg; s.c.) in combination with the repeated cocaine treatment regimen, no enhancement of cocaine-induced place conditioning was seen. Similarly, the kappa-agonist C169593 administered on days 1 to 5 or only on days 3 to 5 of the cocaine treatment regimen prevented the enhanced response to cocaine. This effect occurred after either systemic (0.04-0.16 mg/kg; s.c.) or intracerebroventricular (1.0 mg) treatment and was abolished by the kappa-opioid receptor antagonist, nor-binaltorphimine. In contrast to its effects when administered in combination with cocaine, prior administration of U69593, alone, failed to modify the conditioned response to cocaine. Microdialysis studies revealed a marked elevation of extracellular dopamine levels within the ventral striatum after repeated cocaine administration. In animals that had received U69593 in combination with cocaine, no elevation of dopamine was seen. These data demonstrate that sensitization develops to the conditioned rewarding effects of cocaine and that the activation of central nervous system kappa-opioid receptors prevents the development of this phenomenon, An involvement of the mesolimbic dopamine system in mediating the interaction of kappa-agonists with cocaine is suggested.
引用
收藏
页码:545 / 554
页数:10
相关论文
共 50 条
  • [31] EFFECTS OF SPINAL KAPPA-OPIOID RECEPTOR AGONISTS ON THE RESPONSIVENESS OF NOCICEPTIVE SUPERFICIAL DORSAL HORN NEURONS
    HYLDEN, JLK
    NAHIN, RL
    TRAUB, RJ
    DUBNER, R
    PAIN, 1991, 44 (02) : 187 - 193
  • [32] Peripheral kappa-opioid agonists for visceral pain
    Rivière, PJM
    BRITISH JOURNAL OF PHARMACOLOGY, 2004, 141 (08) : 1331 - 1334
  • [33] DEFINING THE ANTIPRURITIC POTENTIAL OF KAPPA-OPIOID AGONISTS
    COWAN, A
    RYAN, RR
    WHEELERACETO, H
    FASEB JOURNAL, 1995, 9 (03): : A98 - A98
  • [34] Psychotomimetic Effects of Kappa Opioid Receptor Agonists
    White, Kate L.
    Roth, Bryan L.
    BIOLOGICAL PSYCHIATRY, 2012, 72 (10) : 797 - 798
  • [35] Structure, dynamics, and binding modes of selective kappa-agonists on the kappa-opioid receptor.
    Subramanian, G
    Paterlini, MG
    Ferguson, DM
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1998, 216 : U751 - U752
  • [36] Potential for Kappa-Opioid Receptor Agonists to Engineer Nonaddictive Analgesics: A Narrative Review
    Kaski, Shane W.
    White, Allison N.
    Gross, Joshua D.
    Siderovski, David P.
    ANESTHESIA AND ANALGESIA, 2021, 132 (02): : 406 - 419
  • [37] KAPPA-OPIOID AND DELTA-OPIOID RECEPTOR DENSITIES FOLLOWING CHRONIC REPEATED COCAINE ADMINISTRATION
    UNTERWALD, EM
    KREEK, MJ
    REGULATORY PEPTIDES, 1994, : S225 - S226
  • [38] Cellular mechanism for anti-analgesic action of agonists of the kappa-opioid receptor
    Pan, ZZ
    Tershner, SA
    Fields, HL
    NATURE, 1997, 389 (6649) : 382 - 385
  • [39] KAPPA-OPIOID RECEPTOR AGONISTS SUPPRESS ABSENCE SEIZURES IN WAG/RIJ RATS
    PRZEWLOCKA, B
    LASON, W
    MACHELSKA, H
    VANLUIJTELAAR, G
    COENEN, A
    PRZEWLOCKI, R
    NEUROSCIENCE LETTERS, 1995, 186 (2-3) : 131 - 134
  • [40] Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential?
    Albert-Vartanian, A.
    Boyd, M. R.
    Hall, A. L.
    Morgado, S. J.
    Nguyen, E.
    Nguyen, V. P. H.
    Patel, S. P.
    Russo, L. J.
    Shao, A. J.
    Raffa, R. B.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2016, 41 (04) : 371 - 382